임상시험용 물품 시장 규모, 점유율, 성장 및 세계 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of clinical trial supplies Market

The global clinical trial supplies market is experiencing strong growth due to the increasing number of clinical studies, rising pharmaceutical and biotechnology research activities, and the growing adoption of decentralized and hybrid clinical trials. According to the report, the global clinical trial supplies market size was valued at USD 5.45 billion in 2025. The market is projected to grow from USD 5.83 billion in 2026 to USD 11.80 billion by 2034, exhibiting a CAGR of 9.2% during the forecast period. North America dominated the market with a 38.16% market share in 2025, driven by a high concentration of pharmaceutical companies, advanced clinical research infrastructure, and increasing investment in drug development.

Clinical trial supplies include investigational medicinal products, comparator drugs, ancillary supplies, and specialized services such as packaging, labeling, storage, cold-chain logistics, inventory management, and distribution. These supplies ensure the safe, efficient, and compliant execution of clinical trials while maintaining product quality and patient safety throughout the research process.

Market Definition and Scope

Clinical trial supplies play a critical role in supporting pharmaceutical, biotechnology, and medical device research by ensuring investigational products reach trial sites and patients safely and efficiently. Supply management includes manufacturing support, packaging, labeling, blinding, temperature-controlled storage, logistics, depot management, and Direct-to-Patient (DTP) delivery services.

The market serves clinical trials across biologics, small molecules, medical devices, cell and gene therapies, and other advanced therapies. Increasing outsourcing of supply chain management to specialized service providers continues to expand the market scope globally.

Market Dynamics

Drivers

The growing number of clinical trials worldwide remains the primary driver of market growth. Pharmaceutical, biotechnology, and medical device companies continue investing heavily in research and development to introduce innovative therapies across oncology, cardiology, infectious diseases, neurology, and other therapeutic areas. This significantly increases demand for reliable clinical trial supply management services.

Another major growth driver is the rapid adoption of decentralized and hybrid clinical trials. The increasing use of Direct-to-Patient (DTP) delivery, digital inventory management, temperature monitoring, and real-time supply tracking improves operational efficiency while enhancing patient participation and trial accuracy.

Trends

One of the most significant market trends is the integration of digital technologies and automation into clinical trial supply chains. Electronic data capture, cloud-based inventory systems, RTSM/IRT platforms, ePRO solutions, and AI-powered logistics management are helping sponsors improve inventory visibility, minimize wastage, and optimize global clinical trial operations.

Additionally, patient-centric supply models such as remote dispensing, home delivery, and digital accountability systems are becoming increasingly common, improving convenience for participants while supporting decentralized clinical research.

Restraints

High operational costs remain a key restraint for the clinical trial supplies market. Specialized packaging, cold-chain transportation, storage, regulatory compliance, import/export documentation, inventory forecasting, and temperature-controlled logistics significantly increase overall supply management costs. Delays in patient recruitment and protocol amendments further contribute to supply inefficiencies and product wastage.

Impact of Growing Clinical Research

The continuous expansion of global clinical research is creating strong demand for efficient clinical trial supply services. Increasing investment in biologics, biosimilars, personalized medicine, and cell & gene therapies requires highly specialized logistics and supply chain solutions. At the same time, emerging countries are strengthening clinical research infrastructure, creating additional opportunities for global supply providers.

Segmentation Analysis

By type, the services segment dominated the market in 2025 due to rising outsourcing of packaging, labeling, storage, distribution, comparator sourcing, depot management, and Direct-to-Patient (DTP) delivery services. The products segment is also expected to witness steady growth during the forecast period.

By phase, Phase III clinical trials accounted for the largest market share of 51.4% in 2025, supported by increasing late-stage drug development activities worldwide.

By modality, small molecules held the largest 44.1% market share in 2025, driven by growing approvals and relatively easier manufacturing processes. Medical devices are expected to record significant growth during the forecast period.

By therapeutic area, oncology remained the leading segment due to the increasing prevalence of cancer and rising investment in oncology drug development.

By end user, pharmaceutical and biotechnology companies dominated the market owing to growing R&D expenditure and the increasing number of global clinical trials.

Regional Insights

North America led the global clinical trial supplies market with a valuation of USD 2.08 billion in 2025. The region benefits from advanced healthcare infrastructure, a large number of pharmaceutical companies, and strong clinical research activities, particularly in the United States.

Europe remains the second-largest regional market, supported by increasing clinical trial activities and strong regulatory frameworks promoting pharmaceutical innovation.

Asia Pacific is expected to witness substantial growth due to rising healthcare expenditure, expanding pharmaceutical manufacturing, and increasing clinical trial activities across China, Japan, and India. Latin America and the Middle East & Africa are also experiencing gradual expansion as healthcare infrastructure and research investments continue to improve.

Competitive Landscape

The global clinical trial supplies market is highly competitive, with companies focusing on acquisitions, digital technologies, logistics expansion, and service innovation to strengthen their market position. Major industry participants include Thermo Fisher Scientific Inc., Parexel International (MA) Corporation, Catalent Inc., Almac Group, PCI Pharma Services, Clinigen Limited, Myonex, Biocair, Oximio, and KLIFO. Strategic acquisitions, AI-powered supply management platforms, and expansion of clinical logistics networks continue to enhance competition within the industry.

Report Coverage

This report provides a comprehensive analysis of the global clinical trial supplies market, covering market size and forecast for 2025, 2026, and 2034. It includes detailed insights into market drivers, trends, restraints, segmentation by type, phase, modality, therapeutic area, end user, regional outlook, competitive landscape, and recent industry developments influencing future market growth.

Conclusion

The global clinical trial supplies market is projected to grow from USD 5.45 billion in 2025 to USD 11.80 billion by 2034, driven by the increasing number of clinical trials, expanding pharmaceutical research, growing adoption of decentralized clinical studies, and continuous advancements in digital supply chain technologies. Rising investments in biologics, personalized medicine, and innovative clinical trial services are expected to support sustained market growth throughout the forecast period.

Segmentation By Type, Phase, Modality, Therapeutic Area, End User, and Region

By Type * Products

• Investigational Medicinal Products
• Comparator Drugs
• Ancillary Supplies
• Others
• Services
  • Manufacturing Services
  • Packaging, Labeling & Blinding Services
  • Storage & Distribution Services
  • Others

By Phase * Phase I

• Phase II
• Phase III
• Phase IV

By Modality * Small Molecules

• Biologics
• Medical Devices
• Others

By Therapeutic Area * Oncology

• Infectious Diseases
• Neurology
• Cardiology
• Others

By End User * Pharmaceutical & Biotechnological Companies

• Medical Device Companies
• CROs
• Others

By Region * North America (By Type, By Phase, By Modality, By Therapeutic Area, By End User, and by Country)

• U.S. (By Phase)
• Canada (By Phase)
• Europe (By Type, By Phase, By Modality, By Therapeutic Area, By End User, and by Country/Sub-region)
  • U.K. (By Phase)
  • Germany (By Phase)
  • France (By Phase)
  • Italy (By Phase)
  • Spain (By Phase)
  • Scandinavia (By Phase)
  • Rest of Europe (By Phase)
• Asia Pacific (By Type, By Phase, By Modality, By Therapeutic Area, By End User, and by Country/Sub-region)
  • China (By Phase)
  • Japan (By Phase)
  • India (By Phase)
  • Australia (By Phase)
  • Southeast Asia (By Phase)
  • Rest of Asia Pacific (By Phase)
• Latin America (By Type, By Phase, By Modality, By Therapeutic Area, By End User, and by Country/Sub-region)
  • Brazil (By Phase)
  • Mexico (By Phase)
  • Rest of Latin America (By Phase)
• Middle East & Africa (By Type, By Phase, By Modality, By Therapeutic Area, By End User, and by Country/Sub-region)
  • GCC (By Phase)
  • South Africa (By Phase)
  • Rest of the Middle East & Africa (By Phase)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Challenges
• 3.5. Market Trends

4. Key Insights

• 4.1. Number of Clinical Trials, Key Countries/Regions, 2025
• 4.2. Overview of R&D Expenditures, Key Players
• 4.3. Key Industry Developments - Mergers, Acquisitions & Partnerships

5. Global Clinical Trial Supplies Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Products
    • 5.1.1.1. Investigational Medicinal Products
    • 5.1.1.2. Comparator Drugs
    • 5.1.1.3. Ancillary Supplies
    • 5.1.1.4. Others
  • 5.1.2. Services
    • 5.1.2.1. Manufacturing Services
    • 5.1.2.2. Packaging, Labeling & Blinding Services
    • 5.1.2.3. Storage & Distribution Services
    • 5.1.2.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Phase
  • 5.2.1. Phase I
  • 5.2.2. Phase II
  • 5.2.3. Phase III
  • 5.2.4. Phase IV
• 5.3. Market Analysis, Insights and Forecast - By Modality
  • 5.3.1. Small Molecules
  • 5.3.2. Biologics
  • 5.3.3. Medical Devices
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 5.4.1. Oncology
  • 5.4.2. Infectious Diseases
  • 5.4.3. Neurology
  • 5.4.4. Cardiology
  • 5.4.5. Others
• 5.5. Market Analysis, Insights and Forecast - By End User
  • 5.5.1. Pharmaceutical & Biotechnological Companies
  • 5.5.2. Medical Device Companies
  • 5.5.3. CROs
  • 5.5.4. Others
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Clinical Trial Supplies Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Products
    • 6.1.1.1. Investigational Medicinal Products
    • 6.1.1.2. Comparator Drugs
    • 6.1.1.3. Ancillary Supplies
    • 6.1.1.4. Others
  • 6.1.2. Services
    • 6.1.2.1. Manufacturing Services
    • 6.1.2.2. Packaging, Labeling & Blinding Services
    • 6.1.2.3. Storage & Distribution Services
    • 6.1.2.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Phase
  • 6.2.1. Phase I
  • 6.2.2. Phase II
  • 6.2.3. Phase III
  • 6.2.4. Phase IV
• 6.3. Market Analysis, Insights and Forecast - By Modality
  • 6.3.1. Small Molecules
  • 6.3.2. Biologics
  • 6.3.3. Medical Devices
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 6.4.1. Oncology
  • 6.4.2. Infectious Diseases
  • 6.4.3. Neurology
  • 6.4.4. Cardiology
  • 6.4.5. Others
• 6.5. Market Analysis, Insights and Forecast - By End User
  • 6.5.1. Pharmaceutical & Biotechnological Companies
  • 6.5.2. Medical Device Companies
  • 6.5.3. CROs
  • 6.5.4. Others
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
    • 6.6.1.1. By Phase
  • 6.6.2. Canada
    • 6.6.2.1. By Phase

7. Europe Clinical Trial Supplies Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Products
    • 7.1.1.1. Investigational Medicinal Products
    • 7.1.1.2. Comparator Drugs
    • 7.1.1.3. Ancillary Supplies
    • 7.1.1.4. Others
  • 7.1.2. Services
    • 7.1.2.1. Manufacturing Services
    • 7.1.2.2. Packaging, Labeling & Blinding Services
    • 7.1.2.3. Storage & Distribution Services
    • 7.1.2.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Phase
  • 7.2.1. Phase I
  • 7.2.2. Phase II
  • 7.2.3. Phase III
  • 7.2.4. Phase IV
• 7.3. Market Analysis, Insights and Forecast - By Modality
  • 7.3.1. Small Molecules
  • 7.3.2. Biologics
  • 7.3.3. Medical Devices
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 7.4.1. Oncology
  • 7.4.2. Infectious Diseases
  • 7.4.3. Neurology
  • 7.4.4. Cardiology
  • 7.4.5. Others
• 7.5. Market Analysis, Insights and Forecast - By End User
  • 7.5.1. Pharmaceutical & Biotechnological Companies
  • 7.5.2. Medical Device Companies
  • 7.5.3. CROs
  • 7.5.4. Others
• 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.6.1. U.K.
    • 7.6.1.1. By Phase
  • 7.6.2. Germany
    • 7.6.2.1. By Phase
  • 7.6.3. France
    • 7.6.3.1. By Phase
  • 7.6.4. Spain
    • 7.6.4.1. By Phase
  • 7.6.5. Italy
    • 7.6.5.1. By Phase
  • 7.6.6. Scandinavia
    • 7.6.6.1. By Phase
  • 7.6.7. Rest of Europe
    • 7.6.7.1. By Phase

8. Asia Pacific Clinical Trial Supplies Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Products
    • 8.1.1.1. Investigational Medicinal Products
    • 8.1.1.2. Comparator Drugs
    • 8.1.1.3. Ancillary Supplies
    • 8.1.1.4. Others
  • 8.1.2. Services
    • 8.1.2.1. Manufacturing Services
    • 8.1.2.2. Packaging, Labeling & Blinding Services
    • 8.1.2.3. Storage & Distribution Services
    • 8.1.2.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Phase
  • 8.2.1. Phase I
  • 8.2.2. Phase II
  • 8.2.3. Phase III
  • 8.2.4. Phase IV
• 8.3. Market Analysis, Insights and Forecast - By Modality
  • 8.3.1. Small Molecules
  • 8.3.2. Biologics
  • 8.3.3. Medical Devices
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 8.4.1. Oncology
  • 8.4.2. Infectious Diseases
  • 8.4.3. Neurology
  • 8.4.4. Cardiology
  • 8.4.5. Others
• 8.5. Market Analysis, Insights and Forecast - By End User
  • 8.5.1. Pharmaceutical & Biotechnological Companies
  • 8.5.2. Medical Device Companies
  • 8.5.3. CROs
  • 8.5.4. Others
• 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.6.1. Japan
    • 8.6.1.1. By Phase
  • 8.6.2. Australia
    • 8.6.2.1. By Phase
  • 8.6.3. China
    • 8.6.3.1. By Phase
  • 8.6.4. India
    • 8.6.4.1. By Phase
  • 8.6.5. Southeast Asia
    • 8.6.5.1. By Phase
  • 8.6.6. Rest of Asia Pacific
    • 8.6.6.1. By Phase

9. Latin America Clinical Trial Supplies Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Products
    • 9.1.1.1. Investigational Medicinal Products
    • 9.1.1.2. Comparator Drugs
    • 9.1.1.3. Ancillary Supplies
    • 9.1.1.4. Others
  • 9.1.2. Services
    • 9.1.2.1. Manufacturing Services
    • 9.1.2.2. Packaging, Labeling & Blinding Services
    • 9.1.2.3. Storage & Distribution Services
    • 9.1.2.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Phase
  • 9.2.1. Phase I
  • 9.2.2. Phase II
  • 9.2.3. Phase III
  • 9.2.4. Phase IV
• 9.3. Market Analysis, Insights and Forecast - By Modality
  • 9.3.1. Small Molecules
  • 9.3.2. Biologics
  • 9.3.3. Medical Devices
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 9.4.1. Oncology
  • 9.4.2. Infectious Diseases
  • 9.4.3. Neurology
  • 9.4.4. Cardiology
  • 9.4.5. Others
• 9.5. Market Analysis, Insights and Forecast - By End User
  • 9.5.1. Pharmaceutical & Biotechnological Companies
  • 9.5.2. Medical Device Companies
  • 9.5.3. CROs
  • 9.5.4. Others
• 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.6.1. Brazil
    • 9.6.1.1. By Phase
  • 9.6.2. Mexico
    • 9.6.2.1. By Phase
  • 9.6.3. Rest of Latin America
    • 9.6.3.1. By Phase

10. Middle East & Africa Clinical Trial Supplies Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Products
    • 10.1.1.1. Investigational Medicinal Products
    • 10.1.1.2. Comparator Drugs
    • 10.1.1.3. Ancillary Supplies
    • 10.1.1.4. Others
  • 10.1.2. Services
    • 10.1.2.1. Manufacturing Services
    • 10.1.2.2. Packaging, Labeling & Blinding Services
    • 10.1.2.3. Storage & Distribution Services
    • 10.1.2.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Phase
  • 10.2.1. Phase I
  • 10.2.2. Phase II
  • 10.2.3. Phase III
  • 10.2.4. Phase IV
• 10.3. Market Analysis, Insights and Forecast - By Modality
  • 10.3.1. Small Molecules
  • 10.3.2. Biologics
  • 10.3.3. Medical Devices
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 10.4.1. Oncology
  • 10.4.2. Infectious Diseases
  • 10.4.3. Neurology
  • 10.4.4. Cardiology
  • 10.4.5. Others
• 10.5. Market Analysis, Insights and Forecast - By End User
  • 10.5.1. Pharmaceutical & Biotechnological Companies
  • 10.5.2. Medical Device Companies
  • 10.5.3. CROs
  • 10.5.4. Others
• 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.6.1. GCC
    • 10.6.1.1. By Phase
  • 10.6.2. South Africa
    • 10.6.2.1. By Phase
  • 10.6.3. Rest of Middle East & Africa
    • 10.6.3.1. By Phase

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Thermo Fisher Scientific Inc.
  • 11.2.2. Parexel International (MA) Corporation
  • 11.2.3. Catalent Inc.
  • 11.2.4. Almac Group
  • 11.2.5. PCI Pharma Services
  • 11.2.6. Clinigen Limited
  • 11.2.7. Myonex
  • 11.2.8. Biocair
  • 11.2.9. Oximio
  • 11.2.10. KLIFO